Mural Oncology was spun out of Alkermes plc last year to continue development of the IL-2 cytokine nemvaleukin, a promising immuno-oncology asset with a notably challenging mechanism. The company is establishing business operations, fine-tuning clinical trials and working on the next assets it plans to move into the clinic as it awaits key data readouts on nemvaleukin.
Key Takeaways
- CEO Caroline Loew talked to Scrip about Mural’s progress since the business was spun out from Alkermes.
CEO Caroline Loew talked to Scrip in an interview about Mural’s progress since the business separated from Alkermes in November....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?